Expression of Stem Cell and Epithelial-mesenchymal Transition Markers in Primary Breast Cancer Patients with Circulating Tumor Cells

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2012 Jan 24

PMID 22264265

Citations 146

Authors

Sabine Kasimir-Bauer

Oliver Hoffmann

Diethelm Wallwiener

Rainer Kimmig

Tanja Fehm

Affiliations

Soon will be listed here.

Abstract

Introduction: The presence of circulating tumor cells (CTC) in breast cancer might be associated with stem cell-like tumor cells which have been suggested to be the active source of metastatic spread in primary tumors. Furthermore, to be able to disseminate and metastasize, CTC must be able to perform epithelial-mesenchymal transition (EMT). We studied the expression of three EMT markers and the stem cell marker ALDH1 in CTC from 502 primary breast cancer patients. Data were correlated with the presence of disseminated tumor cells (DTC) in the bone marrow (BM) and with clinicopathological data of the patients.

Methods: A total of 2 × 5 ml of blood was analyzed for CTC with the AdnaTest BreastCancer (AdnaGen AG) for the detection of EpCAM, MUC-1, HER2 and beta-Actin transcripts. The recovered c-DNA was additionally multiplex tested for three EMT markers [TWIST1, Akt2, phosphoinositide kinase-3 (PI3Kα)] and separately for the tumor stem cell marker ALDH1. The identification of EMT markers was considered positive if at least one marker was detected in the sample. Two BM aspirates from all patients were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.

Results: Ninety-seven percent of 30 healthy donor samples investigated were negative for EMT and 95% for ALDH1 transcripts, respectively. CTC were detected in 97/502 (19%) patients. At least one of the EMT markers was expressed in 29% and ALDH1 was present in 14% of the samples, respectively. Interestingly, 5% of the ALDH1-positive and 18% of the EMT-positive patients were CTC-negative based on the cut-off level determined for CTC-positivity applying the AdnaTest BreastCancer. DTC in the BM were detected in 107/502 (21%) patients and no correlation was found between BM status and CTC positivity (P = 0.41). The presence of CTC, EMT and ALDH1 expression was not correlated to any of the prognostic clinical markers.

Conclusions: Our data indicate that (1) a subset of primary breast cancer patients shows EMT and stem cell characteristics and (2) the currently used detection methods for CTC are not efficient to identify a subtype of CTC which underwent EMT. (3) The clinical relevance on prognosis and therapy response has to be further evaluated in a prospective trial.

Citing Articles

Current biological implications and clinical relevance of metastatic circulating tumor cells.

Shahhosseini R, Pakmehr S, Elhami A, Shakir M, Alzahrani A, Al-Hamdani M Clin Exp Med. 2024; 25(1):7.

PMID: 39546080 PMC: 11567993. DOI: 10.1007/s10238-024-01518-6.

Extracellular Vesicle-Mediated Modulation of Stem-like Phenotype in Breast Cancer Cells under Fluid Shear Stress.

Brown S, Radcliffe M, Danner J, Andujar Cruz W, Lackey K, Park H Biomolecules. 2024; 14(7).

PMID: 39062471 PMC: 11274421. DOI: 10.3390/biom14070757.

The TGFβ2-Snail1-miRNA Circuitry is Critical for the Development of Aggressive Functions in Breast Cancer.

Luo L, Xu N, Fan W, Wu Y, Chen P, Li Z Clin Transl Med. 2024; 14(2):e1558.

PMID: 38299307 PMC: 10831563. DOI: 10.1002/ctm2.1558.

Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance.

Rapanotti M, Cugini E, Campione E, Di Raimondo C, Costanza G, Rossi P Int J Mol Sci. 2023; 24(14).

PMID: 37511550 PMC: 10380315. DOI: 10.3390/ijms241411792.

Prognostic value of epithelial-mesenchymal transition circulating tumor cells in female breast cancer: A meta-analysis.

Zhao Q, Li B, Gao Q, Luo Y, Ming L Front Oncol. 2022; 12:1024783.

PMID: 36530995 PMC: 9749886. DOI: 10.3389/fonc.2022.1024783.

References

Slade M, Payne R, Riethdorf S, Ward B, Zaidi S, Stebbing J . Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer. 2008; 100(1):160-6. PMC: 2634698. DOI: 10.1038/sj.bjc.6604773. View

Kallergi G, Mavroudis D, Georgoulias V, Stournaras C . Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med. 2007; 13(1-2):79-88. PMC: 1869618. DOI: 10.2119/2006-00083.Kallergi. View

Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E . Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2010; 129(2):417-23. DOI: 10.1002/ijc.25690. View

Bidard F, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P . Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2009; 21(4):729-733. DOI: 10.1093/annonc/mdp391. View

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S . Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002; 20(16):3404-12. DOI: 10.1200/JCO.2002.08.135. View

Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer E, Wallwiener D . Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009; 11(4):R59. PMC: 2750121. DOI: 10.1186/bcr2349. View

Ignatiadis M, Georgoulias V, Mavroudis D . Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer. 2008; 44(18):2726-36. DOI: 10.1016/j.ejca.2008.09.033. View

Sieuwerts A, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M . Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009; 101(1):61-6. PMC: 2639293. DOI: 10.1093/jnci/djn419. View

10.

Hauch S, Zimmermann S, Lankiewicz S, Zieglschmid V, Bocher O, Albert W . The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 2007; 27(3A):1337-41. View

11.

Andreopoulou E, Yang L, Rangel K, Reuben J, Hsu L, Krishnamurthy S . Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer. 2011; 130(7):1590-7. DOI: 10.1002/ijc.26111. View

12.

Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B . Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2009; 16(1):45-55. PMC: 2874875. DOI: 10.1158/1078-0432.CCR-09-1630. View

13.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

14.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A . Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24(23):3756-62. DOI: 10.1200/JCO.2005.04.5948. View

15.

Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R . Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat. 2008; 115(3):581-90. DOI: 10.1007/s10549-008-0143-x. View

16.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

17.

Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland J . Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2005; 118(8):2013-9. DOI: 10.1002/ijc.21576. View

18.

Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P . Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer. 2011; 21(5):822-30. DOI: 10.1097/IGC.0b013e318216cb91. View

19.

Monteiro J, Fodde R . Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer. 2010; 46(7):1198-203. DOI: 10.1016/j.ejca.2010.02.030. View

20.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S . Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009; 27(13):2177-84. DOI: 10.1200/JCO.2008.18.0497. View